Trial Profile
A Randomised, Double-Blind, Parallel Group, Phase 3, Efficacy and Safety Study of AZD6140 Compared With Clopidogrel for Prevention of Vascular Events in Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Nov 2022
Price :
$35
*
At a glance
- Drugs Ticagrelor (Primary) ; Aspirin; Clopidogrel
- Indications Acute coronary syndromes; Cardiovascular disorders
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms PLATO
- Sponsors AstraZeneca
- 01 Nov 2022 Results assessing Biomarker-Based Prediction( from two trials NCT00391872 and NCT00527943) of Recurrent Ischemic Events in Patients With Acute Coronary Syndromespublished in the Journal of the American College of Cardiology
- 11 Jul 2022 Results assessing cardiovascular outcomes in patients with DM presenting with ACS, stratified by PAD status from 4 randomized post-ACS trials (PLATO, APPRAISE-2, TRILOGY, and TRACE) published in the American Journal of Cardiology.
- 15 Nov 2021 Results (N=47,474), pooled analysis of data from 4 multicenter randomized trials (APPRAISE-2, PLATO, TRACER and TRILOGY ACS) presented at the American Heart Association Scientific Sessions 2021